Prefabricated alginate-drug bandages
The invention provides a solution to the drawbacks associated with conventional alginate dressings. This invention features improved alginate dressings or bandages as well as a fabrication process that results in an alginate sheet that is preloaded with drug, can be stored in a freeze-dried state, and is compliant and ready to use at the time of administration.
1. A composition comprising a cryo-organized, crosslinked alginate structure comprising a therapeutic agent and a woven mesh, wherein said composition comprises a Young's modulus of 100 kiloPascals to 10,000 kiloPascals at room temperature.
2. The composition of claim 1 , wherein said cryo-organized structure comprises a network of interconnected crosslinked pores.
3. The composition of claim 1 , wherein said therapeutic agent comprises substance P.
4. A method of promoting wound healing or tissue repair, comprising contacting a tissue of a subject with the composition of claim 1 .
5. The method of claim 4 , wherein said therapeutic agent comprises substance P.
6. The method of claim 4 , wherein the wound is a diabetic wound.
7. The method of claim 6 , wherein the diabetic wound comprises an ischemic wound.
8. The composition of claim 1 , wherein said structure comprises a Young's modulus of to 1,000 kiloPascals to 10,000 kiloPascals at room temperature.
9. The composition of claim 1 , wherein said structure comprises a Young's modulus of 1,000 kiloPascals to 5,000 kiloPascals at room temperature.
10. The composition of claim 1 , wherein the thickness of said composition is 0.1 mm-10 mm.
11. The composition of claim 1 , wherein said alginate comprises non-oxidized alginate.
12. The composition of claim 1 , wherein said alginate comprises oxidized alginate.
13. The composition of claim 1 , wherein said therapeutic agent is a wound-healing or tissue repair compound.
14. The composition of claim 13 , wherein said therapeutic agent is selected from the group consisting of substance P, Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, Stromal cell-Derived Factor, Epidermal Growth Factor, Transforming Growth Factor, Granulocyte Macrophage-Colony Stimulating Factor, and Fibroblast Growth Factor.
15. The composition of claim 3 , wherein said substance P is selected from the group consisting of a SP peptide, a SP-related molecule, a SP fragment, and a SP peptide derivative.
16. The composition of claim 15 , wherein said substance P comprises:
(i) an amino acid sequence that is at least 50% identical to the amino acid sequence of SEQ ID NO: 1 or 2;
(ii) an amino acid sequence that is at least residues 1-8 of SEQ ID NO: 1 or 2;
(iii) the amino acid sequence of SEQ ID NO: 1;
(iv) the amino acid sequence of SEQ ID NO: 2; or
(v) a consensus amino acid sequence, wherein the consensus amino acid sequence comprises Xaa 1 -Pro-Xaa 2 -Pro-Xaa 3 -Xaa 4 -Xaa 5 -Xaa 6 (SEQ ID NO: 12).
17. The composition of claim 2 , wherein said pores have a diameter of 10 μm-100 μm, 100 μm-200 μm, 100 μm-400 μm, or 300 μm-800 μm.
18. The composition of claim 17 , wherein the alginate is crosslinked ionically.
19. The composition of claim 1 , wherein said woven mesh is a gauze.
20. The composition of claim 1 , wherein said woven mesh is interspersed within the alginate structure.
21. The composition of claim 1 , further comprising a backing material.
22. The composition of claim 1 , further comprising a cell.